Beranda › Limfoma Non-Hodgkin › Arizona
Uji klinis Limfoma Non-Hodgkin di Arizona
14 studi untuk Limfoma Non-Hodgkin mencari peserta di lokasi di Arizona.
Kota di Arizona
Teks studi resmi (Bahasa Inggris)
A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma
- GC2202 Study Site 118, Bullhead City
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Sep 2026 · NCT05645107A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Honor Health Research Institute, Scottsdale
- University of Arizona Cancer Center, Tucson
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT05006716A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
- Mayo Clinic - Scottsdale, Scottsdale
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07226843TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- Cancer Treatment Centers of America-Phoenix, Phoenix
Menerima pesertaFase 2
Usia 12 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT02693535A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
- Mayo Clinic in Arizona - Phoenix, Phoenix
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 14 Sep 2026 · NCT06090539Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
- Banner MD Anderson Cancer Center, Gilbert
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 5 Agu 2026 · NCT06116110A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- Banner MD Anderson Cancer Center, Gilbert
- Honor Health, Scottsdale
- Mayo Clinic Arizona, Scottsdale
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 4 Agu 2026 · NCT07188558DALY II USA/ MB-CART2019.1 for DLBCL
- Banner MD Anderson Cancer Center, Gilbert
- Mayo Clinic, Phoenix
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 13 Jul 2026 · NCT04792489A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Banner MD Anderson Cancer Center, Gilbert
- Phoenix Children's Hospital, Phoenix
- University of Arizona Medical Center - Tucson, Tucson
Menerima pesertaStudi observasional
Semua usia · Semua jenis kelamin · Diperbarui 6 Jul 2026 · NCT01351545CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- St. Joseph's Hospital and Medical Center, Phoenix
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 16 Apr 2026 · NCT03328078A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma
- City of Hope Phoenix, Goodyear
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 27 Mar 2026 · NCT06915246Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- Kingman Regional Medical Center, Kingman
- Cancer Center at Saint Joseph's, Phoenix
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Mar 2026 · NCT06418204Study of SGR-1505 in Mature B-Cell Neoplasms
- Banner Health - MD Anderson Cancer Center, Gilbert
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 13 Feb 2026 · NCT05544019SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Scottsdale
Menerima pesertaStudi observasional
Semua usia · Semua jenis kelamin · Diperbarui 28 Okt 2025 · NCT03452774Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.